[Clinical experimentation with HIV vaccines: scientific and ethical dilemmas].
Developing a vaccine against HIV is one of the greatest challenges the scientific community faces today. Several vaccine candidates have undergone preliminary safety and immunogenicity studies in humans. Research teams are ready to test these vaccines in the field, yet the scientific community is divided as to whether efficacy trial should begin. This paper addresses the complex scientific and ethical issues raised by clinical trials. Considering the pressure to act rapidly to solve the crisis, scientists need to hold to the fundamental principles that guide decisions in biomedical research: respect for persons, beneficence and justice. Because these studies need to enroll a large number of subjects, prospective vaccines will need to be tested in developing, as well as industrial countries. The international community needs to work to ensure that the populations that accept the risk of the research receive the full benefit of that research and, that the vaccine proven successful, be made accessible and affordable to people in less economically developed situation.
Lallemant
M
M
Harvard School of Public Health, Cancer Biology Department, Boston, MA 02115, USA.
Le Coeur
S
S
D016915:AIDS Vaccines / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000401:mortality; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D019049:Developed Countries; D003906:Developing Countries; D004992:Ethics, Medical; D005260:Female; D015497:HIV-1 / Q000276:immunology; D015498:HIV-2 / Q000276:immunology; D006801:Humans; D008297:Male; D010817:Physician-Patient Relations; D012106:Research; D012959:Socioeconomic Factors; D014944:World Health Organization
D016915:AIDS Vaccines
Expérimentation clinique des vaccins contre le VIH: dilemmes scientifiques et éthiques.